

Key abstracts accepted by ACR include:

Molecule/disease state	Abstract title	Abstract number/ presentation details
Ianalumab		
Sjögren's disease	Ianalumab demonstrates significant reduction in disease activity in patients with Sjögren's Disease: Efficacy and safety results from two global Phase 3, randomized, placebo-controlled double-blind studies (NEPTUNUS-1 and NEPTUNUS-2)	Abstract #LB24 Oral presentation Oct. 29, 9:15 am – 9:30 am CST
Sjögren's disease	Evaluation of the dual mode of action of Ianalumab (VAY736) in the circulation and salivary gland tissue of patients with Sjögren's Disease: Results from a Phase 2 mechanistic study	Abstract #2296 Poster presentation Oct. 28, 10:30 am – 12:30 pm CST
Sjögren's disease	Ianalumab's dual mode of action: targeting B cells through enhanced B cell depletion and blockade of B cell activating factor receptor signaling	Abstract #0903 Poster presentation Oct. 27, 10:30 am – 12:30 pm CST
Systemic lupus erythematosus	Achieving sustained lupus low disease activity state and remission with Ianalumab (VAY736) in patients with systemic lupus erythematosus: A post hoc analysis from a phase II study	Abstract #0801 Oral presentation Oct. 26, 1:00 pm – 1:15pm CST
Rapcabtagene autoleucel		
Systemic lupus erythematosus	Biomarker data from an open-label, Phase 1/2 Study for YTB323 (Rapcabtagene Autoleucel, a rapidly manufactured CD19 CAR-T therapy) suggest reset of the B Cell compartment in severe refractory SLE	Abstract #2696 Oral Presentation Oct. 29, 12:15pm – 12:30 pm CST
Cosentyx (secukinumab)		
Psoriatic arthritis	Comparison of incidence of psoriatic arthritis in patients with psoriasis treated with interleukin-17 inhibitors vs interleukin-23 inhibitors, interleukin-12/23 inhibitors, and tumor necrosis factor inhibitors in real-world practice: a retrospective study	Abstract #2689 Oct. 29, 12:15pm – 12:30 pm CST